Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.
Institutional & Insider Ownership
21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 10.5% of Capricor Therapeutics shares are held by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Capricor Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 48.94 | -$40.47 million | ($1.80) | -13.24 |
| Maravai LifeSciences | $259.18 million | 3.88 | -$144.85 million | ($0.84) | -4.68 |
Capricor Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Capricor Therapeutics and Maravai LifeSciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 0 | 9 | 0 | 2.80 |
| Maravai LifeSciences | 1 | 4 | 4 | 0 | 2.33 |
Capricor Therapeutics currently has a consensus target price of $40.82, suggesting a potential upside of 71.22%. Maravai LifeSciences has a consensus target price of $5.25, suggesting a potential upside of 33.59%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Maravai LifeSciences.
Profitability
This table compares Capricor Therapeutics and Maravai LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -71.00% | -56.13% |
| Maravai LifeSciences | -62.88% | -22.42% | -12.11% |
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
